(photo credit: (www.genome.gov))
Newswise — An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, reports that abnormal sequences of DNA known as rare copy number variants, or CNVs, appear to play a significant role in the risk for early onset bipolar disorder.
The findings will be published in the December 22 issue of the journal Neuron.
CNVs are genomic alterations in which there are too few or too many copies of sections of DNA. Researchers have known that spontaneously occurring (de novo) CNVs – genetic mutations not inherited from parents – significantly increase the risk for some neuropsychiatric conditions, such as schizophrenia or the autism spectrum disorders. But their role was unclear in bipolar disorder, previously known as manic depression.
Principal investigator Jonathan Sebat, PhD, assistant professor of
psychiatry and cellular and molecular medicine at UC San Diego’s
Institute of Genomic Medicine, and colleagues, found that de novo CNVs
contribute significant genetic risk in about 5 percent of early onset
bipolar disorder, which appears in childhood or early adulthood.
In other words, said the study’s first author Dheeraj Malhotra,
assistant project scientist in Sebat’s lab, “having a de novo mutation
increases the chances of having an earlier onset of disease.”
The cause or causes of bipolar disorder remain unclear. There is a clear
genetic component – the disease runs in families – but previous studies
that have focused mainly on common inherited variants have met with
limited success in identifying key susceptibility genes.
Malhotra said that – while the findings do not conclusively pinpoint a
specific gene or genomic region – the new findings show “convincing”
evidence that rare copy number mutations strongly contribute to the
development of early onset bipolar disorder. He added that sequencing of
complete genomes or exomes of large number of bipolar families is
needed to determine the total genetic contribution of all forms of de
novo mutation to risk for bipolar disorder.
Funding for this research came, in part, from the National Institutes of
Health, Ted and Vada Stanley, the Beyster family foundation, Wellcome
Trust, Science Foundation Ireland, the Sidney R. Baer, Jr. Foundation
and the Essel Foundation.
Co-authors of the study are Shane McCarthy, Stanley Institute for
Cognitive Genomics, Cold Spring Harbor Laboratory; Jacob J. Michaelson,
Beyster Center for Genomics of Psychiatric Diseases and UC San Diego
Department of Psychiatry; Vladimir Vacic, Department of Computer
Science, Columbia University and Stanley Institute for Cognitive
Genomics; Katherine E. Burdick, Mount Sinai School of Medicine; Seungtai
Yoon, Seaver Autism Center, Mount Sinai School of Medicine; Sven
Cichon, Department of Genomics, Life and Brain Center, Institute of
Human Genetics, University of Bonn and Institute of Neuroscience and
Medicine; Aiden Corvin and Michael Gill, Neuropsychiatric Genetics
Research Group, Institute of Molecular Medicine and Department of
Psychiatry, Trinity College Dublin; Sydney Gary, Stanley Institute for
Cognitive Genomics, Elliot S. Gershon, Department of Psychiatry and
Behavioral Neuroscience, University of Chicago; Maria Karayiorgou,
Department of Psychiatry, Columbia University; John R. Kelsoe,
Department of Psychiatry and Institute for Genomic Medicine, UC San
Diego; Olga Krastoshevsky, Verena Krause and Deborah L. Levy, Department
of Psychiatry, McLean Hospital; Ellen Leibenluft, Section on Bipolar
Spectrum Disorders, Emotion and Development Branch, NIMH; Vladimir
Makarov, Seaver Autism Center and Stanley Institute for Cognitive
Genomics; Abhishek Bhandari, Beyster Center for Genomics of Psychiatric
Diseases, UC San Diego Department of Psychiatry and Stanley Institute
for Cognitive Genomics; Anil K. Malhotra, Zucker Hillside Hospital;
Francis J. McMahon, Genetic Basis of Moods and Anxiety Disorders, NIMH;
Markus M. Nothen, Department of Genomics, Life and Brain Center,
Institute of Human Genetics, University of Bonn and German Center for
Neurodegenerative Diseases; James B. Potash, Department of Psychiatry,
University of Iowa, Marcella Rietschel, Central Institute of Mental
Health, University of Heidelberg and Thomas G. Schulze, Department of
Psychiatry and Psychotherapy, George-August University, Germany.This article was first published at www.newswise.com